ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies the side effects of ESK981 and nivolumab and to see how well they
work for the treatment of castration resistant prostate cancer that has spread to other
places in the body (metastatic). ESK981 is an investigational drug that targets several
important pathways that are believed to play a role in the spread of cancer. Immunotherapy
with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the
cancer, and may interfere with the ability of tumor cells to grow and spread. This study is
being done to see if giving ESK981 and nivolumab together works better in treating metastatic
castration resistant prostate cancer compared to usual treatments.